Humann Hodjatzadeh

Humann Hodjatzadeh has a diverse work experience spanning multiple industries. Humann started their career at Airbus as a System Engineer from March 2007 to September 2008. Humann then worked in the Project & Program Management Office at Airbus from April 2013 to September 2014. After this, they transitioned to the pharmaceutical industry, joining Akebia Therapeutics as a Financial Analyst from October 2014 to February 2016. Humann was later promoted to Associate Director, Finance from March 2016 to February 2017, and then became the Director of Finance from March 2017 to June 2018. Hodjatzadeh moved on to Magenta Therapeutics, where they held the position of Director of Financial Planning and Analysis from July 2018 to March 2020. Humann was then promoted to Senior Director of Financial Planning and Analysis from March 2020 to October 2020. Subsequently, they joined Saniona as the Senior Director of Financial Planning Analysis from November 2020 to March 2022, and then as the VP of Strategic Planning, Finance from March 2022 to April 2022. Most recently, Hodjatzadeh served as the Head of Financial Planning Analysis at Inozyme Pharma from June 2022 to September 2023. Currently, they hold the position of Vice President, Financial Planning Analysis at Vigil Neuroscience, starting from September 2023.

Humann Hodjatzadeh completed an MBA in Economics and Finance from Bentley University from 2009 to 2011. Prior to that, Hodjatzadeh pursued a Master's degree in Aerospace Dynamics from Cranfield University in 2005 and 2006. Hodjatzadeh's undergraduate studies were focused on Mechanical Engineering and Environmental Technology, earning a Dipl.Ing. degree from Hochschule Bielefeld between 2001 and 2005.